News|Articles|May 28, 2026

Policy Fatigue: The Future of Patient Access in Pharma

Key Takeaways

Understand how “policy fatigue” is shaping access, affordability, and coverage decisions
Identify the key disconnects between formulary coverage and real patient access
Examine how organizations are adapting access, pricing, and patient support in a rapidly evolving environment

Across the pharmaceutical industry, coverage does not inherently mean access. As a result, the industry must overcome "policy fatigue" by rethinking access strategies, pricing models, and organizational integration to bridge the critical gap between product coverage and real-world patient access.

Q&A With Dane Schroeder from BGB Group on Policy Fatigue and Patient Access vs Real-World Coverage in Pharma

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Policy Fatigue: The Future of Patient Access in Pharma

Key Takeaways

Related Content

The Intelligence Economy: Human-Guided AI for Pharma's Next Era

Overcome Barriers to Specialty Medication Adherence

One Connection, Endless Impact: Improving Patient Medication Access

Trending on PharmExec

Taking a Hard Look at Pharma's Traditional Margin Model

Modern Policy Concerns Stemming from 340B

Pharmaceutical Executive Daily: Mereo BioPharma Enters Option and License Agreement with Sentynl Therapeutics

Funding Roundup: Silence Therapeutics, AbCellera Announce IPO Pricing, Beyang, Remepy Close Series A Financing

Beyond the Segment: How Persona Intelligence Helps Refine HCP Engagement at Scale